Baker Avenue Asset Management’s Pfizer PFE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $981K | Buy |
40,733
+15,399
| +61% | +$403K | 0.02% | 303 |
|
|
2026
Q1 | $711K | Buy |
25,334
+1,732
| +7% | +$46.1K | 0.02% | 343 |
|
|
2025
Q4 | $588K | Sell |
23,602
-3,158
| -12% | -$79.6K | 0.01% | 338 |
|
|
2025
Q3 | $682K | Buy |
26,760
+603
| +2% | +$14.9K | 0.02% | 295 |
|
|
2025
Q2 | $634K | Sell |
26,157
-2,570
| -9% | -$59.9K | 0.02% | 278 |
|
|
2025
Q1 | $728K | Buy |
28,727
+2,596
| +10% | +$67.9K | 0.02% | 265 |
|
|
2024
Q4 | $693K | Sell |
26,131
-6,729
| -20% | -$183K | 0.02% | 265 |
|
|
2024
Q3 | $951K | Buy |
32,860
+2,738
| +9% | +$79.9K | 0.03% | 233 |
|
|
2024
Q2 | $843K | Buy |
30,122
+19
| +0.1% | +$523 | 0.03% | 233 |
|
|
2024
Q1 | $835K | Buy |
30,103
+5,529
| +22% | +$153K | 0.03% | 223 |
|
|
2023
Q4 | $707K | Sell |
24,574
-9,342
| -28% | -$282K | 0.03% | 232 |
|
|
2023
Q3 | $1.12M | Buy |
33,916
+1,876
| +6% | +$66.3K | 0.06% | 195 |
|
|
2023
Q2 | $1.18M | Sell |
32,040
-1,852
| -5% | -$72.1K | 0.06% | 173 |
|
|
2023
Q1 | $1.38M | Buy |
33,892
+1,613
| +5% | +$69.7K | 0.07% | 156 |
|
|
2022
Q4 | $1.65M | Sell |
32,279
-4,054
| -11% | -$194K | 0.1% | 134 |
|
|
2022
Q3 | $1.59M | Buy |
36,333
+15,740
| +76% | +$765K | 0.1% | 136 |
|
|
2022
Q2 | $1.08M | Sell |
20,593
-1,569
| -7% | -$80K | 0.07% | 148 |
|
|
2022
Q1 | $1.15M | Sell |
22,162
-1,974
| -8% | -$102K | 0.06% | 157 |
|
|
2021
Q4 | $1.43M | Buy |
24,136
+11,574
| +92% | +$573K | 0.07% | 138 |
|
|
2021
Q3 | $540K | Buy |
12,562
+4,881
| +64% | +$216K | 0.03% | 178 |
|
|
2021
Q2 | $300K | Sell |
7,681
-8,506
| -53% | -$331K | 0.02% | 211 |
|
|
2021
Q1 | $586K | Buy |
16,187
+353
| +2% | +$12.5K | 0.04% | 164 |
|
|
2020
Q4 | $582K | Sell |
15,834
-2,500
| -14% | -$91.7K | 0.04% | 156 |
|
|
2020
Q3 | $638K | Sell |
18,334
-15
| -0.1% | -$526 | 0.05% | 150 |
|
|
2020
Q2 | $569K | Sell |
18,349
-311
| -2% | -$10.6K | 0.05% | 159 |
|
|
2020
Q1 | $577K | Sell |
18,660
-3,655
| -16% | -$125K | 0.07% | 117 |
|
|
2019
Q4 | $829K | Buy |
22,315
+259
| +1% | +$9.22K | 0.06% | 167 |
|
|
2019
Q3 | $751K | Sell |
22,056
-11,130
| -34% | -$405K | 0.06% | 156 |
|
|
2019
Q2 | $1.36M | Sell |
33,186
-521
| -2% | -$20.7K | 0.11% | 119 |
|
|
2019
Q1 | $1.36M | Sell |
33,707
-15,887
| -32% | -$636K | 0.11% | 114 |
|
|
2018
Q4 | $2.05M | Sell |
49,594
-237,702
| -83% | -$9.87M | 0.2% | 89 |
|
|
2018
Q3 | $12M | Buy |
287,296
+25,073
| +10% | +$965K | 0.99% | 32 |
|
|
2018
Q2 | $9.03M | Buy |
262,223
+23,412
| +10% | +$800K | 0.78% | 38 |
|
|
2018
Q1 | $8.04M | Buy |
238,811
+13,891
| +6% | +$478K | 0.73% | 40 |
|
|
2017
Q4 | $7.73M | Buy |
224,920
+8,963
| +4% | +$306K | 0.75% | 37 |
|
|
2017
Q3 | $7.32M | Buy |
215,957
+7,857
| +4% | +$253K | 0.82% | 35 |
|
|
2017
Q2 | $6.63M | Buy |
208,100
+8,613
| +4% | +$272K | 0.88% | 32 |
|
|
2017
Q1 | $6.47M | Sell |
199,487
-4,345
| -2% | -$137K | 0.87% | 33 |
|
|
2016
Q4 | $6.28M | Buy |
203,832
+32,650
| +19% | +$997K | 0.88% | 32 |
|
|
2016
Q3 | $5.5M | Buy |
171,182
+13,885
| +9% | +$464K | 0.79% | 37 |
|
|
2016
Q2 | $5.25M | Buy |
157,297
+9,077
| +6% | +$290K | 0.79% | 39 |
|
|
2016
Q1 | $4.17M | Buy |
148,220
+33,079
| +29% | +$945K | 0.63% | 49 |
|
|
2015
Q4 | $3.53M | Sell |
115,141
-23,758
| -17% | -$747K | 0.51% | 58 |
|
|
2015
Q3 | $4.14M | Sell |
138,899
-15,371
| -10% | -$493K | 0.73% | 40 |
|
|
2015
Q2 | $4.91M | Sell |
154,270
-4,497
| -3% | -$147K | 0.65% | 35 |
|
|
2015
Q1 | $5.24M | Buy |
+158,767
| New | +$5.05M | 0.7% | 31 |
|
Other funds holding PFE
Baker Avenue Asset Management's PFE Position: Q2 2026 in Review
Baker Avenue Asset Management increased its Pfizer (PFE) stake by 61% in Q2 2026, buying an estimated $403K and bringing the position to 40,733 shares worth $981K. The position accounts for 0.02% of the portfolio, ranked #303.
Baker Avenue Asset Management first reported a position in PFE in Q1 2015 and has held it in 46 quarters since. The position peaked at $12M in Q3 2018. 2,823 funds tracked by Wall St. Rank hold PFE as of Q2 2026.
- Baker Avenue Asset Management held 40,733 shares of Pfizer worth $981K as of Q2 2026.
- Baker Avenue Asset Management bought 15,399 Pfizer shares in Q2 2026, an estimated $403K.
- Pfizer made up 0.02% of Baker Avenue Asset Management's portfolio in Q2 2026, its #303 holding.
- Baker Avenue Asset Management first reported a position in Pfizer in Q1 2015 and has held it in 46 quarters since.
- Baker Avenue Asset Management's Pfizer position peaked at $12M in Q3 2018.
- 2,823 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.
Based on Baker Avenue Asset Management's 13F filing for Q2 2026, filed 28 Jul 2026.